(R)-8-(3-Amino-piperidin-1-yl)-7-akā-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3

Linagliptin ʻO Linagliptin, i hoʻomohala ʻia e Boehringer Ingelheim, ua ʻae ʻia e ka FDA ma Mei 2, 2011. Hoʻohana ʻia ia e hoʻohui i ka meaʻai a me ka hoʻoikaika kino e hoʻomaikaʻi i ka mālama ʻana i nā pae glucose koko i nā poʻe me ka maʻi diabetes type 2.Hoʻomaikaʻi ʻo Linagliptin i ka mālama ʻana i ka glucose koko i nā maʻi ma o ka pale ʻana i ka dipeptidyl peptidase-4 (DPP-4).

ʻO ka Incretin (Incretin) ka hopena o ka hoʻoikaika ʻana i ka huna ʻana o ka insulin e nā pancreatic islet B cell, ka mea nui me ka glucose-dependent insulinotropic polypeptide (GIP) a me ka glucagon-like polypeptide-1 (GLP-1).ʻO DDP-4 kahi protease serine aia ma ka ʻili o nā cell.Hoʻopili ia i nā protein a loaʻa nui i loko o ka plasma a me nā ʻiʻo like ʻole o ke kino (e like me ke kīpē, ate, villi ʻōpū liʻiliʻi, nā cell endothelial, etc.).ʻO Linagliptin kahi mea koho DPP-4 inhibitor e kāohi i ka hana o ka enzyme ma o ka hoʻopaʻa ʻana i ka DPP-4, hoʻopaneʻe i ka hoʻohaʻahaʻa ʻana o GLP-1, hoʻonui i ka hana o GLP-1, a hoʻoulu i ke ʻano o ka glucose i hilinaʻi i ka insulin. e hoʻemi ana i ka pae o ka glucagon i ke kahe, a laila e hoʻoponopono i ke kiʻekiʻe o ka glucose koko o nā mea maʻi me ka maʻi diabetes type 2.

Hoʻohālikelike ʻia me nā mea paʻa DPP-4 ʻē aʻe, ʻo nā pono nui o Linagliptin ʻo ia: he palekana maikaʻi loa ia a hiki ke hōʻemi pono i ka hemoglobin glycosylated.Hoʻokuʻu ʻia ʻo Linagliptin i nā feces ma ke ʻano prototype.Ma hope o ka lawelawe waha, ʻo ka renal excretion he 5% wale nō o ka nui i hāʻawi ʻia.ʻOiai inā e lawelawe ʻia me ka intravenously, ʻo 30.8% wale nō i hoʻokuʻu ʻia ma o nā puʻupaʻa.No laila, ʻaʻohe pono o ka poʻe maʻi e mālama ana.E nānā mau i ka hana o ke ake a me ke kīkī a me ka hoʻoponopono ʻana.Hiki i nā poʻe maʻi āpau ke hoʻoponopono like i ka maʻi no ka maʻalahi o ke kau ʻana.
ʻO nā hopena ʻino maʻamau o ka Linagliptin ʻo ia ka maʻi hanu, ka ihu o ka ihu, ka ʻeha ʻiʻo, ke poʻo a me ka ʻeha ʻāʻī.